1. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015;313:2263-73.
[PUBMED]
2. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013;10:686-90.
[CROSSREF] [PUBMED]
3. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-85.
[CROSSREF] [PUBMED]
4. Rhee EJ. Nonalcoholic fatty liver disease and diabetes: an epidemiological perspective. Endocrinol Metab (Seoul) 2019;34:226-33.
[CROSSREF] [PUBMED] [PMC]
5. Han E, Lee YH. Non-alcoholic fatty liver disease: the emerging burden in cardiometabolic and renal diseases. Diabetes Metab J 2017;41:430-7.
[CROSSREF] [PUBMED] [PMC]
6. Han JM, Kim HI, Lee YJ, Lee JW, Kim KM, Bae JC. Differing associations between fatty liver and dyslipidemia according to the degree of hepatic steatosis in Korea. J Lipid Atheroscler 2019;8:258-66.
[CROSSREF] [PUBMED] [PMC]
7. Li L, Liu DW, Yan HY, Wang ZY, Zhao SH, Wang B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev 2016;17:510-9.
[CROSSREF] [PUBMED]
8. Choi SI, Chung D, Lim JS, Lee MY, Shin JY, Chung CH, et al. Relationship between regional body fat distribution and diabetes mellitus: 2008 to 2010 Korean National Health and Nutrition Examination Surveys. Diabetes Metab J 2017;41:51-9.
[CROSSREF] [PUBMED]
9. Goodpaster BH, Krishnaswami S, Harris TB, Katsiaras A, Kritchevsky SB, Simonsick EM, et al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med 2005;165:777-83.
[CROSSREF] [PUBMED]
10. Subramanian V, Johnston RD, Kaye P, Aithal GP. Regional anthropometric measures associated with the severity of liver injury in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013;37:455-63.
[CROSSREF] [PUBMED]
11. Suzuki A, Abdelmalek MF, Unalp-Arida A, Yates K, Sanyal A, Guy C, et al. Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2010;8:1062-9.
[CROSSREF] [PUBMED] [PMC]
12. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-906.
[CROSSREF] [PUBMED]
13. Lee DH. Noninvasive evaluation of nonalcoholic fatty liver disease. Endocrinol Metab (Seoul) 2020;35:243-59.
[CROSSREF] [PUBMED] [PMC]
14. Lee YH, Bang H, Park YM, Bae JC, Lee BW, Kang ES, et al. Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores. PLoS One 2014;9:e107584.
[CROSSREF] [PUBMED] [PMC]
15. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441-7.
[CROSSREF] [PUBMED]
16. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol 2014;5:211-8.
[CROSSREF] [PUBMED]
17. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013;57:1357-65.
[CROSSREF] [PUBMED]
18. Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol 2012;12:2.
[CROSSREF] [PUBMED] [PMC]
19. Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013;145:782-9.
[CROSSREF] [PUBMED]
20. Lee YH, Jung KS, Kim SU, Yoon HJ, Yun YJ, Lee BW, et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: nationwide surveys (KNHANES 2008-2011). J Hepatol 2015;63:486-93.
[CROSSREF] [PUBMED]
21. Lee YH, Kim SU, Song K, Park JY, Kim DY, Ahn SH, et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: nationwide surveys (KNHANES 2008-2011). Hepatology 2016;63:776-86.
[CROSSREF] [PUBMED]
22. Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci 2014;69:547-58.
[CROSSREF] [PUBMED] [PMC]
23. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl 1):S62-9.
[PUBMED] [PMC]
24. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
[PUBMED]
26. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.
[CROSSREF] [PUBMED] [PMC]
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
[CROSSREF] [PUBMED]
28. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009;137:865-72.
[CROSSREF] [PUBMED]
29. Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010;42:503-8.
[CROSSREF] [PUBMED]
30. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-54.
[CROSSREF] [PUBMED]
31. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007;46:32-6.
[CROSSREF] [PUBMED]
32. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36(4 Pt 1):986-92.
[CROSSREF] [PUBMED]
33. Hu G, Bouchard C, Bray GA, Greenway FL, Johnson WD, Newton RL Jr, et al. Trunk versus extremity adiposity and cardiometabolic risk factors in white and African American adults. Diabetes Care 2011;34:1415-8.
[CROSSREF] [PUBMED] [PMC]
34. Hsing JC, Nguyen MH, Yang B, Min Y, Han SS, Pung E, et al. Associations between body fat, muscle mass, and nonalcoholic fatty liver disease: a population-based study. Hepatol Commun 2019;3:1061-72.
[CROSSREF] [PUBMED] [PMC]
35. Alferink LJ, Trajanoska K, Erler NS, Schoufour JD, de Knegt RJ, Ikram MA, et al. Nonalcoholic fatty liver disease in the rotterdam study: about muscle mass, sarcopenia, fat mass, and fat distribution. J Bone Miner Res 2019;34:1254-63.
[CROSSREF] [PUBMED]
36. Wahrenberg H, Lonnqvist F, Arner P. Mechanisms underlying regional differences in lipolysis in human adipose tissue. J Clin Invest 1989;84:458-67.
[CROSSREF] [PUBMED] [PMC]
37. Shadid S, Koutsari C, Jensen MD. Direct free fatty acid uptake into human adipocytes in vivo: relation to body fat distribution. Diabetes 2007;56:1369-75.
[CROSSREF] [PUBMED]
38. Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab Res Rev 2002;18(Suppl 2):S5-9.
[CROSSREF] [PUBMED]
39. Bolinder J, Engfeldt P, Ostman J, Arner P. Site differences in insulin receptor binding and insulin action in subcutaneous fat of obese females. J Clin Endocrinol Metab 1983;57:455-61.
[CROSSREF] [PUBMED]
40. van Harmelen V, Dicker A, Ryden M, Hauner H, Lonnqvist F, Naslund E, et al. Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. Diabetes 2002;51:2029-36.
[CROSSREF] [PUBMED]